The growth and regression of breast cancer have been known to be influenced by steroid and peptide hormones, including oestrogens, progesterone and prolactin (Lippman et al., 1976; Lippman, 1981; Dao et al., 1982; Kelly et al., 1978; Nagasawa, 1979; Welsch, 1985) . This observation has generated a great deal of hormone receptor research in an attempt to elucidate the endocrine control mechanisms operative in breast cancer. The question of the clinical relevance of prolactin receptors has been addressed by several studies with conflicting results either when a relationship has been sought between steroid receptors and PRLR (Holdaway & Friesen, 1977; Pearson et al., 1978; Thorpe & Daehnfeldt, 1980; RaeVenter et al., 1981; Murphy et al., 1984; Bonneterre et al., 1986; Ben-David et al., 1988b) or when the prognostic role of the PRLR has been investigated (Waseda et al., 1985; Bonneterre et al., 1987) .
In 1978 the study Group of the University of Naples (GUN) promoted a randomised clinical trial to assess the effectiveness of adjuvant Tamoxifen in preventing relapse in operable breast cancer (Bianco et al., 1988) . In this study, unlike other adjuvant trials, oestrogen, progesterone and prolactin receptors were assayed in the same tumour specimen in most patients. The presence and the concentration of oestrogen and progesterone receptors were both significantly related to the length of DFS in TM treated group but not in controls.
The major scope of the present report is to investigate the correlation of PRLR with ER and PgR and to define its prognostic role in primary breast cancer at 10 year follow-up.
Materials and methods
Receptor assay Fragments of tumour tissue were obtained from the operating room and frozen immediately after mastectomy in liquid nitrogen, where they kept stored for up to 2 weeks before processing.
For PRLR determination, microsomal membranes from 229 patients were prepared by differential centrifugation according to Shiu et al. (1973) . The resulting pellets were resuspended in 25 mM Tris-HCI, 10 mM MgCI2, pH 7.6, and stored for about a month in liquid nitrogen until assayed for protein content determinations (Hartree, 1972) and for binding studies (Kelly et al., 1975) . Ovine prolactin (oPRL; NIH PS-10) was iodinated by the lactoperoxidase procedure (Frantz & Turkington, 1972) and purified by Sephadex G-100 chromatography. The specific activity of '25I-oPRL was 160 ± 8.5 tCi Ag-'. Each membrane preparation (0.3 mg protein) was incubated in triplicate with approximately 10' c.p.m. of 251I-oPRL in a final volume of 0.3 ml assay buffer (25 mM Tris-HCl, 10 mM MgCI2, 1% bovine serum albumin, pH 7.4). Similar duplicate incubations for each membrane sample containing 1 Lg of unlabelled o-PRL were used for non-specific binding determination. The incubations were performed at room temperature for 16 h and were stopped by the addition of 3 ml of ice cold buffer. Bound and free '251I-oPRL were separated by low-speed centrifugation; the supernatants were decanted and the radioactivity bound to the membranes was counted in a Packard gamma counter. The specific binding was calculated by subtracting the mean of the two non-specific binding measurement from each of the three individual total binding values of the same membrane preparation. Lyophilised liver membranes from pregnant rabbits were utilised as control in the PRLR assay. The intra and inter-assay variation coefficients were respectively 7% and 10%. No significant differences were found between assays either in the range or in the mean level of PRLR. The mean of the specific binding was expressed as percentage of the total counts added to the incubation medium per 0.3 mg of membrane protein. Values of specific binding less than 1% were considered negative.
ER as well as PgR were assayed, in a single laboratory, using the destran coated charcoal technique (McGuire et al., 1977; Pichon & Milgrom, 1977 (Bianco et al., 1988) . The data of this study were included in the Early Breast Cancer Triallists' Collaborative Group Overview on mortality from primary breast cancer (EBCTCG, 1988 (Kaplan & Meier, 1958) was used to estimate DFS. Overall survival was not analysed because of the limited number of events. Comparison between curves was carried out by the MantelHaenszel procedure (Mantel, 1966) . The Cox's proportional hazard regression model (Cox, 1972) (Bianco et al., 1988) . All probability values were two-sided.
Results
Distribution of tumours as function of their PRLR levels is shown in Figure 1 . PRLR was positive in 75/229 (32.8%) patients, whose characteristics are summarised in Table II. No differences were observed between PRLR positive (PRLR +) and negative (PRLR -) in age, menopausal and nodal status and treatment allocation. No significant association was found between PRLR and either ER or PgR (P = 0.37 and P = 0.49 respectively) (Table III) . Spearman's rank correlation coefficients were also calculated on the basis of the hormonal receptors amount (Table IV) . No evidence was observed of a relationship between PRLR and ER or PgR while a highly significant correlation was found between ER and PgR.
No differences in DFS were observed between PRLR + and PRLR -patients (P = 0.67) (Figure 2 ). The DFS curve of PRLR unknowns was almost superimposable with those pertaining to PRLR + and PRLR -patients (data not shown). Similar results were found in ER + and in ER -as well as in PgR + and PgR -subgroups or in treated and untreated patients (data not shown).
The prognostic significance of PRLR and a potential interaction with the effects of adjuvant TM-treatment were further investigated by adding them up into a Cox regression model, in which nodal, menopausal and ER/PgR status, TM-treatment and first order interaction between ER/PgR status and TM-treatment were entered as covariates. In a previous report (Bianco et al., 1988) , indeed, ER and PgR were found to affect DFS in treated but not in control patients. Introduction of PRLR without and with TM-PRLR interaction into the model did not significantly increase likelihood of the model (Table V) , that is prolactin receptor neither was an independent prognostic factor nor affected the efficacy of adjuvant therapy with TM.
Discussion
The role of prolactin in the development and growth of experimental rat and mouse mammary tumours is well estab- (Manni et al., 1977; Costlow et al., 1975; Welsch & Gribler, 1973) , and PRL stimulates the growth of many human breast cancer cell lines in vitro (Malarkey et al., 1983; Manni et al., 1986; Biswas & Vonderhaar, 1987 (Manni et al., 1977; De Sombre et al., 1976) , in cultured cancer cell lines (Shiu et al., 1987) and in human breast cancer specimens (Holdaway & Friesen, 1977; Pearson et al., 1978; Thorpe & Daehnfeldt, 1980; Rae-Venter et al., 1981; Turcot-Lemay & Kelly, 1982; Murphy et al., 1984; Bonneterre et al., 1986; Ben-David et al., 1988a,b (Holdaway & Friesen, 1977; Pearson et al., 1978; Thorpe & Daehnfeldt, 1980; Rae-Venter et al., 1981; Ben-David et al., 1988b) . The lack of relationship between PRLR and steroid receptors suggests that these receptors are independently expressed.
By contrast, a positive correlation between PRLR and steroid receptors in breast carcinoma was reported only by Murphy et al. (1984) and Bonneterre et al. (1986) . Murphy et al. observed a significant correlation between ER and PRLR in cultured human breast cancer cells and in just a low number of breast tumour biopsies. The study of Bonneterre et al. (1986) is the largest in the literature. However, looking at the strength of correlation, the coefficient values, although statistically significant, are very low, especially those referring to free PRLR, which are directly comparable with our data (Spearman correlation= 0.11 for ER and 0.10 for PgR). In addition, linear correlation values of 0.074 and 0.05 (both not significant) were observed between free PRLR and ER and PgR respectively, when only non-zero values of both receptors were studied. Total PRLR was found to correlate with ER and PgR only in post-menopausal patients, r values never being greater than 0.30. On the basis of the previous considerations it seems reasonable to argue that a positive correlation between PRLR and steroid receptors, if any, is very low with a minor biological and clinical relevance.
To our knowledge, the prognostic significance of PRLR has been evaluated by only two other groups of authors (Waseda et al., 1985; Bonneterre et al., 1987) in non-controlled clinical studies. Waseda et al. observed a significantly worse survival in PRLR + than the PRLR -patients. In his study, however, univariate analysis was performed without adjusting for other relevant prognostic factors. Bonneterre et al. reported that PRLR was a significantly favourable prognostic factor for DFS in subgroups of patients and only in association with steroid receptors. However, these results were not adjusted for treatment.
In our study at 10 year follow-up there was no evidence of an independent prognostic role of PRLR on DFS. Furthermore, no interaction was found between the effect of adjuvant therapy with TM and prolactin receptor. This conclusion confirms previous observation by Pearson et al. (1978) Finally, the lack of correlation between steroid receptors and PRLR might open new avenues in the treatment of breast cancer, e.g. the combining of* anti-oestrogens or LH-RH analogues with bromocriptine or somatostatin analogues, in order to achieve complete suppression of both oestrogen and prolactin activity.
